



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

June 17, 2019

Amit Kumar  
President and Chief Executive Officer  
Anixa Biosciences, Inc  
3150 Almaden Expressway, Suite 250  
San Jose, CA 95118

**Re: Anixa Biosciences, Inc**  
**Registration Statement on Form S-3**  
**Filed June 11, 2019**  
**File No. 333-232067**

Dear Dr. Kumar:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Ronald (Ron) Alper at 202-551-3329 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Beverages, Apparel and  
Mining

cc: Barry Grossman